Cervical Cytology
The Pap test : principles of collection and preparation of specimens. Laboratory organisation, screening and reporting cervical smears.
The Pap Test
Collection of specimens
Guidelines on laboratory organisation, processing and screening
Terminology and reporting

Terminology and categories for reporting cervical smears

  • Historical perspective
    It is widely acknowledged that the  criteria and terminology used to interpret and report cervical smears differs country to country. This has led to problems of communication between cytopathologists , cytotechnologists and clinicians and  makes it difficult for epidemiologists to make valid comparisons of the effectiveness of the different cervical screening programmes. The variability in terminology impedes meaningful discussion between laboratories and also affects patient management and the introduction of optimal methods of patient  care.
  • The problem was addressed in 1988, by the National Cancer Institute in the United States who prepared a reporting system for cervical cytology which is known as The Bethesda System (TBS). In1990, the Leonardo da Vinci programme  sponsored the preparation of the Equivalent Terminology Tables which compared the many systems of reporting cervical smears in the European Union with the Bethesda system. See Equivalent Terminology
  • The partners involved in the preparation of  Eurocytology website have opted to use  the terminology proposed in The Bethesda System in view of its world wide application.  Wherever appropriate links to the Equivalent Terminology have been maintained.

The main categories of the Bethesda reporting system (2001) are shown below

2001 Bethesda System
Equivalent Terminology
  • Satisfactory for evaluation (describe presence or absence of endocervical/transformation zone component and other quality indicators e.g. partially obscuring blood etc)
  • Satisfactory for evaluation
  • Satisfactory for evaluation but limited by (specify reason)
  • Specimen rejected/not processed (specify reason)
  • Unsatisfactory for evaluation (specify reason)
  • Specimen process and examined but unsatisfactory for evaluation of epithelial abnormality because of (specify reason)

OTHER MALIGNANT NEOPLASMS (specify)

For further information relating to Bethesda follow these links www.bethesda2001.cancer.gov/ 


 

Back
End of module - Return to Training Package 1